JMP Securities Reiterates Market Perform Rating on Incyte (INCY)

JMP Securities analyst Reni J. Benjamin reiterated a Market Perform rating on Incyte (NASDAQ: INCY).

The analyst comments "We reiterate our Market Perform rating for Incyte. Recently, Incyte announced Monjuvi met its primary endpoint during the Phase 3 inMIND trial in r/r FL as well as the FDA approval of Niktimvo (axatilimab) in cGVHD. While there are multiple data updates in 4Q24/1Q25 and the company has a cash position of $1.45B, we continue to believe that shares are fairly valued until the rux patent cliff is dealt with, ideally with a meaningful acquisition."

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $62.16 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Costco reports May net sales of $24.01 billion, up 14.5% from year ago
• American Resources receives Nasdaq notice for late 10-Q filing